These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16460457)

  • 1. Fibrinolytic activity is highly influenced by long-term glycemic control in Type 1 diabetic patients.
    Seljeflot I; Larsen JR; Dahl-Jørgensen K; Hanssen KF; Arnesen H
    J Thromb Haemost; 2006 Mar; 4(3):686-8. PubMed ID: 16460457
    [No Abstract]   [Full Text] [Related]  

  • 2. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients.
    Iorio A; Federici MO; Mourvaki E; Ferolla P; Piroddi M; Stabile A; Timi A; Celleno R; Benedetti MM
    Thromb Haemost; 2007 Sep; 98(3):635-41. PubMed ID: 17849053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normal tissue plasminogen activator and plasminogen activator inhibitor activity in plasma from patients with type 1 diabetes mellitus.
    Vicari AM; Viganó D'Angelo S; Testa S; Comi G; Galardi G; Orsi E; D'Angelo A
    Horm Metab Res; 1992 Nov; 24(11):516-9. PubMed ID: 1452117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10 years of follow-up.
    Rautio A; Boman K; Eriksson JW; Svensson MK
    Diab Vasc Dis Res; 2016 May; 13(3):183-91. PubMed ID: 26818227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
    Aso Y; Wakabayashi S; Yamamoto R; Matsutomo R; Takebayashi K; Inukai T
    Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus.
    Carmassi F; Morale M; Puccetti R; De Negri F; Monzani F; Navalesi R; Mariani G
    Thromb Res; 1992 Sep; 67(6):643-54. PubMed ID: 1440530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
    Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selected new atherosclerosis risk factors and markers of fibrinolysis in children and adolescents with obesity, hypertension and diabetes].
    Głowińska B; Urban M; Koput A; Galar M
    Przegl Lek; 2003; 60(1):12-7. PubMed ID: 12884639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents with type 1 diabetes mellitus: relation to diabetic micro-vascular complications and carotid intima media thickness.
    Adly AA; Elbarbary NS; Ismail EA; Hassan SR
    J Diabetes Complications; 2014; 28(3):340-7. PubMed ID: 24581943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulation and fibrinolysis variables in pregnant women with type 1 diabetes mellitus.
    Bronisz A; Rosc D; Bronisz M; Szymanski W; Junik R
    Med Sci Monit; 2008 Nov; 14(11):CR574-9. PubMed ID: 18971874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of fibrinolysis and hyperlipidaemia with quantitative sensory tests in an epidemiological study of Swedish type 1 diabetic patients.
    Lithner F; Bergenheim T; Borssén B; Dahlén G; Nilsson TK
    Diabet Med; 1995 Jul; 12(7):590-4. PubMed ID: 7554780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
    Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
    Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.
    Tehrani S; Mobarrez F; Antovic A; Santesson P; Lins PE; Adamson U; Henriksson P; Wallén NH; Jörneskog G
    Thromb Res; 2010 Sep; 126(3):e225-31. PubMed ID: 20637495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study.
    Simpson AJ; Booth NA; Moore NR; Lewis SJ; Gray RS
    Acta Diabetol; 1999 Sep; 36(3):155-8. PubMed ID: 10664320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes.
    Baker NL; Hunt KJ; Stevens DR; Jarai G; Rosen GD; Klein RL; Virella G; Lopes-Virella MF;
    Diabetes Care; 2018 Jan; 41(1):128-135. PubMed ID: 29118060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients.
    McGill JB; Schneider DJ; Arfken CL; Lucore CL; Sobel BE
    Diabetes; 1994 Jan; 43(1):104-9. PubMed ID: 8262307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coagulation and fibrinolytic systems in type I diabetes: effects of venous occlusion and insulin-induced hypoglycaemia.
    Wieczorek I; Pell AC; McIver B; MacGregor IR; Ludlam CA; Frier BM
    Clin Sci (Lond); 1993 Jan; 84(1):79-86. PubMed ID: 8382139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diabetes, coagulation and vascular events].
    Nenci GG; Paliani U
    Recenti Prog Med; 2000 Feb; 91(2):86-90. PubMed ID: 10748654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
    Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.